NEW YORK (TheStreet) -- Wednesday was a strong session for a number of stocks, and here are three biotechnology plays, in particular, to watch for more upside.

Agios Pharmaceutical (AGIO) - Get Reportpopped as high as $76.98 on Wednesday, before backing off and closing at $73.83, up 92 cents on nearly 1 million shares. It wasn't a great close, but it was a new post-initial public offering high.

With strong momentum, the stock still appears to have more upside. If the market cooperates, this stock could get up to $80 and then $88 to $90.

Natus Medical , after a big fourth-quarter run last year, the stock consolidated for six months, popped in July, consolidated for a couple more months and recently broke out again. It has been choppy in the past few weeks, but on Wednesday it popped 55 cents to $32.80 on 865,000 shares.

That is the biggest volume since January. The stock rose as high as $33.20 intraday, a new all-time high, and, with the stock positioned near the bottom of its long-term channel, it appears to have more room to run. 

Regulus Therapeutics (RGLS) - Get Report had a spectacular day Wednesday on strong Hepatitis C drug news. This stock exploded almost 200% at one point from Tuesday's close at the $6 level to as high as $18.33 on Wednesday pre-market.

It got as low as $11.13 intraday before closing at $13.75, up 6.98, or 103%, on 20 million shares. If it can get back above $15 to $15.20, this could be an $18 to $19 stock.

At the time of publication, the author held no positions in any of the stocks mentioned.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.